Drug Trial Radar · NCT05163288
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
Jun 30, 2022
Primary completion
Jun 12, 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- IntraBio IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care. Following this randomized, double-blind, placebo-controlled "Parent Study", an extension phase is conducted for (1) patients who completed the "Parent Study" and (2) patients who are enrolled directly into the Extension Phase. Currently, the Extension Phase provides patients with 3 years of open-label treatment.
Conditions
- Niemann-Pick Disease, Type C
Interventions
N-Acetyl-L-LeucineDrug
N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
PlaceboOther
Matching Placebo Sachet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)
- Modified Scale for the Assessment and Rating of Ataxia (US only)Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Completed
The Royal Melbourne Hospital
Parkville, Victoria, Australia · Active not recruiting
First Faculty of Medicine, Charles University Hospital Prague
Prague, Czechia · Active not recruiting
University of Giessen
Giessen, Germany · Active not recruiting
University of Hamburg
Hamburg, Germany · Completed
SphinCS - Institute of Clinical Science in Lysosomal Storage Disorders
Höchheim, Germany · Active not recruiting
Ludwig Maximilian University of Munich
München, Germany · Not yet recruiting
University Hospital Münster
Münster, Germany · Active not recruiting
Amsterdam UMC
Amsterdam, Netherlands · Recruiting
Comenius University in Bratislva
Bratislava, Slovakia · Active not recruiting
University Hospital Bern Inselspital
Bern, Switzerland · Active not recruiting
Great Ormond Street Hospital
London, United Kingdom · Active not recruiting
Royal Free London NHS Foundation Trust
London, United Kingdom · Active not recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.